Baidu
map

Cell:建立人类树突状细胞与辅助性T细胞相互作用模型 ​

2019-10-13 佚名 BioArt

细胞-细胞相互作用异常复杂,涵盖大量分子与信号通路,学界钻研多年,仍旧是管中窥豹。来自法国巴黎PSL研究大学的Vassili Soumelis团队于在Cell杂志上发表题为A Quantitative Multivariate Model of Human DendriticCell-T Helper Cell Communication的文章,建立了实验与理论相结合的研究方法,实验上,在蛋白质水

细胞-细胞相互作用异常复杂,涵盖大量分子与信号通路,学界钻研多年,仍旧是管中窥豹。来自法国巴黎PSL研究大学的Vassili Soumelis团队于在Cell杂志上发表题为A Quantitative Multivariate Model of Human DendriticCell-T Helper Cell Communication的文章,建立了实验与理论相结合的研究方法,实验上,在蛋白质水平检测了细胞所分泌的细胞因子与应激反应;理论上,建立了信号输入输出之间的联系和相互作用关系。作者以人类树突状细胞(Dendritic cell,简称DC)与辅助性T细胞(T Helper cell,简称Th)之间的相互作用为研究对象,分析了36例DC相关的信号分子和17种Th分泌的细胞因子,并依靠这些数据建立数学模型,演算出56种已经被实验证实的细胞相互关系,与此同时,还推测出290种可能关系,并证实了IL-12p70可以通过IL-1信号通路诱导17型辅助性T细胞(简称Th17)。

首先,作者采集了人类单核细胞来源的DC(MoDCs)和外周血液CD11c+DC(bDCs)两类细胞,并刺激24小时。所采用的刺激信号主要包含三大类共计14种。

第一种:内源信号分子,包括干扰素beta(interferon β,简称IFN-β),GM-CSF, TSLP和 PGE2;

第二种:Toll样受体的配基,包括Toll4受体的激动剂脂多糖( lipopolysaccharide,简称LPS),Toll1/2受体激动剂PAM3CSK4,Dectin1激动剂Curdlan,Toll2/Dectin1激动剂 zymosan,Toll7/8受体激动剂R848,Toll3受体激动剂 poly(I:C) 和NLRP3炎症小体活化剂硫酸铝钾;

第三种:细菌病毒,包括高温灭活的Candida albicans (简称HKCA),李斯特菌(Listeria monocytogenes,简称HKLM),Staphylococcus aureus (简称HKSA), Streptococcus pneumoniae (简称HKSP)和流感病毒(influenza virus,简称flu)。

接下来,作者通过流式细胞术等方法,检测了36种DC相关分子的表达情况,其中,29种处于细胞表面,7种处于细胞分泌上清之中。结果显示,除了一些已知的DC细胞响应之外,作者还有了一些新的发现:(1)zymosan刺激的MoDCs 表达高水平的CD54 和PVR;(2)流感病毒刺激的MoDCs可以诱导ICOSL;(3)LPS刺激的MoDCs 可以诱导高水平的CD30L和CD83。

再下来,作者将这些刺激过的DC与T细胞共培养6天,随后检测Th的增殖效率以及17种Th相关细胞因子的表达分泌情况。有趣的是,作者将Th和DC的表现相互比较,发现,这二者之间并不存在一一对应的关系,也就是说,两种刺激物对DC产生的效果类似,但是,这两种刺激物所处理的DC与T细胞共培养之后,产生的效果很可以截然不同。

接着,作者采用生物信息学的方法,以上述实验数据建立模型。简单来说,作者综合DC输出的36种信号分子和Th输出的17种效应分子,将两两之间的关系简化为“正向调控”和“负向调控”两种,并且,还加入数据库和已发表文献中的信息,建立了复杂的信号调控网络。例如,通过这一模型,作者发现, IL-10的负向调控分子包括OX40L, 4-1BBL, IL-12, TNF-α, CD58, VISTA,Galectin-3, CD80, CD29, IL-1, ICAM-3, SLAMF3, IL-28a和CD83,而正向调控分子包括Jagged-2, PDL1, IL-10, CD11a, HLA-DR, ICOSL, CD100, CD30L, CD18, ICAM-2和CD86,这样,给予DC不同的刺激信号,作者就可以推断出Th响应细胞IL-10的表达分泌情况。

最后,作者利用这样模型,试图推测并证实新的细胞相互关系。通过建立的模型,作者发现,IL-12在与IL-1, ICAM-2或者Jagged-2共同分泌时,倾向于调控IL-17F,而与CD70, IL-23或者 LIGHT 共同出现时,则更倾向于调控IL-17A。另外,敲除IL-12,IL-17A和IL-17F的表达水平都显着降低。这些结果说明,IL-12参与Th17的诱导分化。为了进一步探讨IL-12诱导Th17的机制,作者采用体外诱导Th的模型,发现,IL-12并不能直接诱导Th17,但是,同时加入IL-1和IL-12,Th17就诱导出来了。

这是一篇实验与理论相结合的佳作。实验结果与计算建模相互支持,相互指导,相辅相成。如下图所示,实验部分采用了密切关联两部分数据,一是何种刺激下DC细胞的响应,二是响应后的DC对T细胞的作用。理论部分以DC和T细胞的输出细胞因子为核心,建立了细胞因子之间的正向和负向调控网络模型。通过这一模型,作者预测出一些新的细胞间相互关系,最终再用实验证实这些关系是否属实。这篇文章的亮点有两处,一是建立和实验理论相结合研究的范本,二是文章中提供的诸多细胞调控信息以供研究参考。

原始出处:
Grandclaudon M1, Perrot-Dockès M2, Trichot C1, et al.A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication.Cell. 2019 Oct 3;179(2):432-447.e21. doi: 10.1016/j.cell.2019.09.012.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2020-04-28 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2019-10-15 ylz8405
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1871443, encodeId=7a7218e1443b9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 10 02:02:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041079, encodeId=d7b920410e92d, content=<a href='/topic/show?id=8fb693680d4' target=_blank style='color:#2F92EE;'>#辅助性T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93680, encryptionId=8fb693680d4, topicName=辅助性T细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Mon Mar 23 23:02:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961729, encodeId=54501961e297d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 28 22:02:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471644, encodeId=58d914e164440, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Tue Oct 15 09:02:00 CST 2019, time=2019-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909288, encodeId=f46e190928867, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Oct 22 00:02:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047738, encodeId=4f88104e73887, content=梅斯里提供了很多疾病的模型计算公式,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Oct 13 21:02:00 CST 2019, time=2019-10-13, status=1, ipAttribution=)]
    2019-10-13 CHANGE

    梅斯里提供了很多疾病的模型计算公式,赞一个!

    0

相关资讯

JEM:抑制TBK1激酶增强T细胞活力,更好的杀死黑色素瘤癌细胞

这些发现,一反传统的认为TBK1蛋白作为引起免疫反应的功能,首次阐明了TBK1蛋白也有抑制机体免疫反应的功能。证明了树突状细胞的TBK1蛋白在维持免疫系统的动态平衡起到重要作用。尤其是在控制肿瘤细胞的治疗中,同时抑制TBK1可能会引起更强的免疫力。

Circulation:预处理树突状细胞可以改善心梗后的心脏重塑和心功能

tDC治疗具有转化为缺血性组织损伤后抗重塑疗法的潜力。

Nature Methods:科学家们研发出一种人工受体,或将强化抗肿瘤疫苗

树突状细胞(DC)是一种功能强大的抗原呈递细胞,是抗肿瘤免疫疗法的关键细胞。现在,科学家们研发出一种人工受体,能够改善DC呈递抗原的方式,提高免疫细胞识别、攻击肿瘤细胞的效率。这一研究于1月22日在线发表在《Nature methods》期刊。

Sci Transl Med:重磅!抗癌疫苗再获突破,一名晚期患者已5年无癌

今日,《科学》杂志子刊《Science Translational Medicine》上刊登了一项令人激动的研究结果——作为全世界癌症免疫疗法的中心之一,宾夕法尼亚大学的科学家们在抗癌疫苗上做出了重大突破,有望彻底变革当下癌症治疗的格局。

Immunity:免疫细胞在自身免疫性疾病中起着意想不到的作用

一项新的研究为自身免疫性疾病,即系统性红斑狼疮的潜在发病机制提供了有趣的见解。

Cell Research:一招两用——树突状细胞关键调节因子LKB1功能终明了

日前,美国St. Jude儿童医院的研究人员发现了DC中在代谢与免疫过程中发挥重要调节作用的关键因子——LKB1,证实了其在维持正常的免疫稳态和保护性抗肿瘤免疫中的作用,并指出了其作为癌症和自身免疫疾病治疗的重要靶点的巨大潜能。

Baidu
map
Baidu
map
Baidu
map